Scarica l'app Stockscreener
11.60
5.94%
0.65
Dopo l'orario di chiusura:
11.60
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
State Street Corp Buys 396,034 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells $53,547.13 in Stock - MarketBeat
Cullinan Therapeutics' chief medical officer sells $52,851 in stock By Investing.com - Investing.com Australia
Cullinan Therapeutics chief scientific officer sells $53,547 in stock - Investing.com
Cullinan Therapeutics' chief medical officer sells $52,851 in stock - Investing.com India
Cullinan therapeutics chief legal officer sells $39,729 in stock - Investing.com India
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 5.6%What's Next? - MarketBeat
Fmr LLC Purchases 19,681 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Franklin Resources Inc. Sells 252,868 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 4%Here's Why - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.19 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Insider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 3,489 Shares of Stock - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Increase in Short Interest - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Charles Schwab Investment Management Inc. Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Purchased by RTW Investments LP - MarketBeat
Patient Square Capital LP Acquires New Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by Holocene Advisors LP - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Walleye Capital LLC - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Braidwell LP - MarketBeat
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Price Target at $31.67 - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives $31.67 Average Target Price from Brokerages - MarketBeat
Cullinan Therapeutics Announces Q3 2024 Progress and Outlook - TipRanks
What is Leerink Partnrs' Forecast for CGEM FY2025 Earnings? - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 6.3%Time to Sell? - MarketBeat
Blue Owl Capital Holdings LP Adjusts Stake in Cullinan Therapeutics Inc - GuruFocus.com
CGEMCullinan Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Biotechnology Value Fund L.P. Expands Stake in Cullinan Therapeu - GuruFocus.com
Cullinan advances lupus treatment with new clinical trial By Investing.com - Investing.com Canada
Cullinan advances lupus treatment with new clinical trial - Investing.com
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager - The Bakersfield Californian
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - GlobeNewswire Inc.
Cullinan Therapeutics' chief scientific officer sells $125,120 in stock By Investing.com - Investing.com Australia
Cullinan Therapeutics' chief scientific officer sells $125,120 in stock - Investing.com India
Insider Sale: Chief Scientific Officer of Cullinan Therapeutics Inc (CGEM) Sells Shares - GuruFocus.com
Cullinan Therapeutics: Q3 Earnings Snapshot - Darien Times
Cullinan Therapeutics Inc (CGEM) Quarterly 10-Q Report - Quartzy
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Cullinan Therapeutics Advances Pipeline Despite $40.6M Loss; Maintains $639M Cash Position | CGEM Stock News - StockTitan
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - StockTitan
Vanguard Group Inc's Strategic Acquisition in Cullinan Therapeutics Inc - GuruFocus.com
Cullinan Therapeutics to Present Preclinical Data for - GlobeNewswire
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - StockTitan
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $31.67 - MarketBeat
FY2027 Earnings Forecast for CGEM Issued By Leerink Partnrs - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS Group - MarketBeat
Exchange Traded Concepts LLC Sells 2,961 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
SG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):